<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Assembly Biosciences, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        35328338
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       161811
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Assembly Biosciences is a development-stage drug company focused specifically on anal disorders (such as difficile-associated diarrhea, or CDAD) and the treatment of hepatitis B infections. Its primary product is a diltiazem cream for pain associated with anal fissures while a secondary product is a phenylephrine gel for fecal incontinence. Assembly has licensed intellectual property associated with an oral drug delivery system that targets sites within the intestines. Assembly Biosciences is the result of a 2014 merger between Ventrus Biosciences and Assembly Pharmaceuticals.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Financial Performance.flsnp" />
  <p>
   Like any development stage company, Assembly has a history of losses, and it expects to see negative cash flow for the foreseeable future until at least one of its candidates gains regulatory approval for market.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   Assembly continues to push its candidates through the
   <company id="144161">
    FDA
   </company>
   -approval process. Fellow drug maker
   <company id="101250">
    Aptalis
   </company>
   launched a nitroglycerin-based treatment for anal fissure pain in 2012 and
   <company id="102759">
    Salix Pharmaceuticals
   </company>
   launched its treatment for fecal incontinence the same year. The company is moving forward with its treatments and developing its gastrointestinal delivery system that uses a pH-sensitive release mechanism. Possible uses vary from gastrointestinal and metabolic disorders to viral and bacterial vaccines.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
